Drugs / GB491
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05860582 | Sep → Nov 2022 | breast cancer, non-small cell lung carcinoma | Genor Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05337657 | Jun 2021 → Dec 2023 | breast cancer | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05851014 | Jan 2022 → Jan 2026 overdue | breast cancer | Genor Biopharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB491 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05337657 ↗ |
| Route | Oral | “150 mg orally twice daily” NCT05851014 ↗ |